Leerink Partners on Exact Sciences (EXAS): 'Cologuard Plus Pricing Higher vs. Expectations; EXAS Unlikely to Pursue ADLT'
Tweet Send to a Friend
Leerink Partners analyst Puneet Souda reiterated an Outperform rating and $70.00 price target on Exact Sciences (NASDAQ: EXAS)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
